Trial will add immunotherapeutic agent to first cycle of antiviral cocktails.
D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use*; D004351:Drug Resistance; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy; D011070:Poly I-C / Q000008:administration & dosage / Q000627:therapeutic use*; D011072:Poly U / Q000008:administration & dosage / Q000627:therapeutic use*; D017211:Treatment Failure; D019562:Viral Load
D000998:Antiviral Agents; D011072:Poly U; C047490:poly(I).poly(c12,U); D011070:Poly I-C